Combination of Hypofractionated Radiotherapy and Glofitamab for Relapsed or Refractory DLBCL With High Tumor Burden: A Case Series
MedComm – Oncology · 2026-06 · 5 (2)
DOI: 10.1002/mog2.70077 ↗Kurz gefasst
Fachartikel in der Zeitschrift MedComm – Oncology, online erschienen am 04.06.2026. Verfasst von Jingshu Meng und 9 weiteren Autor:innen. Die Arbeit nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Meng, J., Li, Q., Zhu, F., Zhou, L., Liu, X., Liu, T., Qin, C., Pan, H., Ye, B., & Zhang, L. (2026). Combination of Hypofractionated Radiotherapy and Glofitamab for Relapsed or Refractory DLBCL With High Tumor Burden: A Case Series. MedComm – Oncology, 5(2). https://doi.org/10.1002/mog2.70077
Vancouver
Meng J, Li Q, Zhu F, Zhou L, Liu X, Liu T, et al. Combination of Hypofractionated Radiotherapy and Glofitamab for Relapsed or Refractory DLBCL With High Tumor Burden: A Case Series. MedComm – Oncology. 2026;5(2). doi:10.1002/mog2.70077
BibTeX
@article{Meng2026,
author = {Meng, Jingshu and Li, Qiuhui and Zhu, Fang and Zhou, Lu and Liu, Xinxiu and Liu, Tao and Qin, Chunxia and Pan, Huaxiong and Ye, Baixin and Zhang, Liling},
title = {Combination of Hypofractionated Radiotherapy and Glofitamab for Relapsed or Refractory DLBCL With High Tumor Burden: A Case Series},
journal = {MedComm – Oncology},
year = {2026},
volume = {5},
number = {2},
doi = {10.1002/mog2.70077}
}
EUVIMED